#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Treatment of multiple angiomatosis involving the skeleton and the abdominal and thoracic cavities with interferon α, thalidomide and zoledronate


Authors: Z. Adam 1;  L. Křikavová 2;  M. Krejčí 1;  M. Mechl 2;  L. Pour 1;  M. Moulis 3;  J. Vaníček 4;  Č. Neumann 5;  M. Navrátil 1;  K. Veselý 6;  J. Vorlíček 1
Authors‘ workplace: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc. 1;  Radiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří A. Válek, CSc. 2;  Ústav patologie Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jirka Mačák, CSc. 3;  Klinika zobrazovacích metod Lékařské fakulty MU a FN u sv. Anny Brno, přednosta doc. MUDr. Petr Krupa, CSc. 4;  Chirurgická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Zdeněk Kala, Ph. D. 5;  I. patologicko-anatomický ústav Lékařské fakulty MU a FN u sv. Anny Brno, přednostka doc. MUDr. Markéta Hermanová, Ph. D. 6
Published in: Vnitř Lék 2008; 54(6): 653-664
Category: Case Reports

Overview

Multiple angiomatosis is a very rare disease formed by histologically benign angiomas spreading beyond single organ or tissue.In the case reported herein, hemangiomas affected several vertebrae of a young man and spread through his peritoneal cavity projecting to his stomach and causing recurrent hematemesis. Also affected was the mediastinum. The patient suffered from bone pain and digestive problems. Initial treatment involved 2 drugs with antiangiogenic effect: interferon α (initial dose of 6 million units 3 times a week, later reduced to 3 million units 3 times a week due to adverse effects) and zoledronate (4 mg i.v. every 28 days). Even though the therapy eliminated bone pain after 2 months, CT check at later stage showed but little regression of the mass of the angiomas in the abdominal cavity and the mediastinum. Substantial reduction in the mass of the angiomas to merely residual quantity, i.e. partial remission of the disease, was achieved only after the addition of 100 mg/day thalidomide (Myrin) to the above mentioned doses of interferon and zoledronate administered on a regular basis. However, the disease recurred after the therapy was interrupted, and the above triple combination therapy has had to be restored. Maintenance therapy will succeed to repeated achievement of remission of angiomas. A very good therapeutic effect was recorded for combined interferon α, thalidomide and zoledronate in this specific case of multiple angiomatosis.

Key words:
angiomatosis – osetolysis – multiple myeloma – zoledronate – thalidomide – interferon α


Sources

1. Haggstrom AN, Drolet BA, Baselga E et al (Hemangioma Investigators Group). Prospective study of infantile hemangiomas. Demographic, prenatal and perinatal characteristics. J Pediatr 2007; 150: 291-294.

2. Kalousová J. Komplexní léčba hemangiomatózy jater. Čes Slov Pediatr 1994; 49: 698-699.

3. Bláhová K, Mottl M, Tůma S. Hemangiomatóza jater u tříměsíčního kojence. Čes Slov Pediatr 1991; 46: 434-436.

4. Mottl H, Koutecký J, Buncová M et al. Sdružený výskyt preaurikulárního hemangiomu s hemangiomatózou tenkého střeva a mesenteria. Čes Slov Pediatr 1985; 40: 523-526.

5. Mottl H. Teleangiektatický hemangiom: Difúzní hemangiomatóza mesenteria a střeva. Čes Slov Pediatr 1985; 40: 523-526.

6. Srbová J. Hemangiomatóza. Sestra 2005; 15: 46.

7. Langer C, Thonhofer R, Hagenbarth K et al. Diffuse Hämangiomatose von Leber und Milz bei Erwachsenen. Pathologie 2001; 22: 424-428.

8. Ito K, Ichiki T, Ohi K et al. Pulmonary capillary hemangiomatosis with severe pulmonary hypertension. Circ J 2003; 67: 793-795.

9. Kawasaki I, Ito T, Ksuchia T et al. Is angiomatosis an intrinsic pathohistological features of massive osteolysis? Report of an autopsy case and review of the literature. Virchows Arch 2003; 442: 400-406.

10. Dufau JP, Tourneau A, Audouin J et al. Isolated diffuse hemangiomatosis of the spleen with Kasabach-Merrit-like syndrome. Histopathology 1999; 35: 337-344.

11. Kairi-Vassilatou E, Grapa D, Kontogianni-Katsarou K et al. Clinicopathological features of unusual vascular leasions of the pelvis, retroperitoneum and colon in females. A report of five cases and review of the literature. Eur J Gynecol Oncol 2006; 27: 250-255.

12. Bölke E, Gripp S, Peiper M et al. Multifocal epiteloid hemangioendotelioma: a case report of a clinical chemeleon. Eur J Med Res 2006; 11: 1-15.

13. Marinis A, Kairi E, Theodosopoulos T et al. Right colon and liver hemangiomatosis: A case report and review of literature. World J Gastroenterol 2006; 12: 6405-6407.

14. Moon WA, Yy HCh, Lee JM et al. Diffuse hepatic hemangiomatosis in an adult. J Korean Med Sci 2000; 15: 471-474.

15. Blatný J, Štěrba J, Magnová O. Léčba život ohrožujícího krvácení u kojence s hemangiomatózou a s projevy Kasabacha-Merritové pomocí rekombinantního faktoru VIIA. Čes Slov Pediatr 2002; 57: 401-402.

16. Werner JA, Eivazi BJ, Folz AA et al. State of the Art zur Klassifikation, Diagnostik und Terapie von zervikofazialen Hämangiomen und vaskulären Malformationen. Laryngo Rhino Otol 2006; 85: 883-891.

17. Neuman J, Rosioreanu A, Schuss A et al. Radiology Patology Conference: sclerosing hemangioma of the lung. Clinical Imaging 2006; 30: 409-412.

18. Levy AD, Abbot RM, Rohrmann CA et al. Gastrointestinal hemangiomas. AJR Am Roentgenol 2001; 177: 1073-1077.

19. Scafidi DE, Mcleary MS, Young LW. Diffuse neonatal gastrointestinal hemangiomatosis. CT finding. Pediatric Radiol 1998; 28: 512-518.

20. Hsu RM, Horton KM, Fishman EK. Diffuse cavernous hemangiomatosis of the colon. Findings on three dimensional CT colonography. AJR Amer J Roentgenol 2002; 179: 1042-1048.

21. Djouhri A, Arrive L, Bouras T et al. Diffuse cavernous hemangiomatosis of the rectosigmoid colon: imaging findings. J Comp Assist Tomogr 1998; 22: 851-855.

22. Lyon DG, Mantia AG. Large bowel hemangiomas. Dis Colon Rectum 1984; 27: 404-407.

23. Weiss SW, Goldblum J, Enzinger FM et al. Soft Tissue Tumors 4th ed. Philadelphia, PA: Mosby 2001, 891-914.

24. Bank ER, McLeary MS, Young LW. Diffuse neonatal gastrointestinal hemangiomas. CT finding. Radiology 1987; 165: 657-661.

25. Park DDE, Ricketts RR. Infantile gastrointestinal hemangioma as a couse of chronic anemia. South Med J 1992; 85: 201-205.

26. Caseiro-Alves F, Brito J, Araujo AE et al. Liver haemangioma: common and uncommon findings and how to improve the differential diagnosis. Eur Radiol 2007; 15: 300-306.

27. Goodman, P, Dominquez, R, Castillo M. Diffuse, neonatal hemagniomatosis: imaging finding in two patients. J Comp Assist Tomogr 1992; 16: 117-121.

28. Lin ChH, Hsieh HF, Yy JCh et al. Spontaneous rupture of a large exogastric hemangioma. Complicated by hemoperitoneum and sepsis. J Formos Med Ass 2006; 105: 1027-1030.

29. Mulliken JB, Boon LM, Takahashi H et al. Pharmacologic therapy for endangering hemangiomas. Curr Opin Dermatol 1995; 10: 110-113.

30. Hasan Q, Swee TT, Gush J et al. Steroid therapy of a proliferating hemangiomas: histochemical and molecular changes. Pediatrics 2000; 105: 117-121.

31. Uysal KM, Olgun N, Erbay A et al. High dose oral methylprednisolone therapy in childhood. Pediatr Hematol Oncol 2001; 18: 335-341.

32. Hurovitz SA, Hurvitz CH, Sloninsky L et al. Successful treatment with cyclophosphamide of life threatening diffuse hemangiomatosis involving the liver. J Pediatr Hematol Oncol 2000; 22: 527-532.

33. Gottschling S, Schneider G, Meyer S et al. Two infants with life threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide. Pediatr Blood Cancer 2006; 46: 239-242.

34. White CW. Treatment of hemangiomatosis with recombinant interferon alpha. Semin Hematol 1990; 27: 15-22.

35. Takahashi A, Ogawa Ch, Kanazawa T et al. Remission induced by interferon alpha in a patient with massive osteolysis: a severe case of Gorham-Stout syndrome. J Pediatr Surg 2005; 40: 47-50.

36. Nevolová P, Bláhová K, Kabelka Z. Úspěchy léčby rozsáhlé hemangiomatózy u 17měsíčního dítěte po podání interferonu alfa. Ref výběr Dermatovenereol 1996; 2: 83.

37. Harper L, Michael JL, Enjolras O et al. Successful management of a retroperitoneal Kaposiform hemangioendotelioma with Kasabach-Merritt phenomenon using alpha interferon. Eur J Pediatr Surg 2006; 16: 369-372.

38. D´Amato RJ, Loughnan MS, Flynn E et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.

39. Kenyon BM, Browne F, D´Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971-978.

40. Or R, Feferman R, Shoshan S. Thalidomide reduces vascular density in granulomatous tissue of subcutaneously implanted polyvinyl alcohol sponges in Quinea pigs. Exp Hematol 1998; 26: 217-221.

41. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species dependent. Biochem Pharmacol 1998; 55: 1827-1834.

42. Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000; 26: 351-362.

43. Vacca A, Scavelli C, Montefusco V et al. Thalidomide dowregulates angiogenic genes in bone marrow endothelial cell of patients with multiple myeloma. J Clin Oncol 2005; 23: 5334-5346.

44. Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing. Shifting the antiogenic balance. Proc Natl Acad Sci USA 2002; 99: 13243-13247.

45. Masferrer JL, Leahy KM, Koki AT et al. Antiantiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311.

46. Gilheeney SW, Scott, RM, Turner C et al. Treatment of Von Hippel Lindau associated hemangioblastoma in pediatric patients with bevacizumab (Avastin). Neurolo-Oncology 2007; 9: Abstr. 168.

47. Nelson SC, Bostrom BC. Successful use of bevacizumab in live threatening steroid-resistant infantile hepatic hemangioendotelioma. Pediatr Blood Cancer 2007; 48: Abstr. 611.

48. Ramasamy-Karthik Stehen L, Jackie Ch et al. Bevacizumab for POEMS syndrome. Blood 2006; 108: Abstr. 366B.

49. Ziemssen F, Voelker M, Inhoffen W et al. Combined treatment of juxtapapillary haemagnioma with intravitreal bevacizumab and photodynamic therapy. Eye 2007; 21: 1125-1126.

50. Von Buelow M, Pape S, Hoerauf H. Systemic bevacizumab treatment of a juxtapappillary retinal haemangioma. Acta Ophthalmol Scand 2007; 85: 114-116.

51. Meyerle-Catherine B, Bailay FK, Diana I et al. Intravitreal bevacizumab for retinal angiomatous proliferation. Retina 2007; 27: 451-457.

52. Li EC, Davis LE. Zoledronic acid: A new parenteral bisphosphonate. Clin Ther 2003; 25: 2666-2708.

53. Wood JM, Bonjean K, Ruetz S et al. Novel anti-angiogenic effects of the bisphosphonate compound zoledronic acid, a potent inhibitor of bone resorption. J Pharmacol Exp Ther 2002; 302: 1055-1061.

54. Hasmim M, Bieler G, Rüegg C. Zoledronic acid inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 2007; 5: 166-173.

55. Bellahcene A, Chaplet M, Bonjean K et al. Zoledronic acid inhibits alpha-beta3 and alpha-beta5 integrin cell surface expression in endothelial cells. Endothelium 2007; 14: 123-130.

56. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Incest 2004; 114: 623-633.

57. Croucher PI, De Raeve H, Perry M et al. Zoledronic acid treatment of 5T2MM bearing mice inhibits the development of myeloma bone disease: evidence fordecreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18: 482-492.

58. Fournier P, Boissier S, Filleur S et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 2: 6538-6544.

59. Adam Z, Ševčík P, Vorlíček J et al.: Kostní nádorová choroba. Praha: Grada Publishing 2004.

60. Wood J, Bonjean K, Ruetz S et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055-1061.

61. Loo WJ, Lanigan SW. Recent advances in laser therapy for the treatment of cutaneous vascular disorders. Lasers Med Sci 2002; 17: 9-12.

62. Winter H, Drager E, Sterry W. Sclerotherapy for threatment of hemangiomas. Dermatol Surg 2000; 26: 105-108.

63. Geh JLC, Geh VSY, Jemec B et al. Surgical treatment of periocular hemangiomas. A single center experience. Plast Reconstr Surg 2007; 119: 1553-1562.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 6

2008 Issue 6

Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#